Synlogic Shares Positive Data From SYNB1618 Study - SYNLOGIC INC by Synlogic, Inc. (OTC:SYBX)

Synlogic (NASDAQ:SYBX) reported positive data from Phase 1/2a study of SYNB1618 in patients with Phenylketonuria.

Synlogic is a clinical-stage company applying synthetic biology to probiotic bacteria to develop novel living medicines.

Phenylketonuria is a rare genetic condition that causes an amino acid called phenylalanine to build up in the body. SYNB1618 is an oral, investigational medicine designed to metabolize phenylalanine as a treatment for phenylketonuria.

Synlogic shares closed Friday's session at $8.12. The stock has a 52-week high of $14.59 and a 52-week low of $5.75.

Ohr Pharmaceutical Merger With Neubase Therapeutics Approved By Shareholders

Earn 8% APY on a Real Estate-Backed Note from $5,000

Promoted by EquityMultiple(17b disclosure)

EquityMultiple's Alpine Notes have distributed $478M+ with no missed payments. Accredited investors can start with $5,000 at a fixed 8% APY for 6 months.

SYBXSYNLOGIC INC by Synlogic, Inc.

$1.10-1.79%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.